UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/769,404	01/26/2001	Theo Wallimann	8932-296	4809

20582 7590 07/13/2007

JONES DAY
222 East 41st Street
New York, NY 10017-6702

EXAMINER	
WANG, SHENGJUN	
ART UNIT	**PAPER NUMBER**
1617	

MAIL DATE	DELIVERY MODE
07/13/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	09/769,404	WALLIMANN ET AL.	
	Examiner	Art Unit	
	Shengjun Wang	1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *17 April 2007*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *23,24 and 31-41* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *23,24 and 31-41* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on APRIL 17, 2007 has been entered.

Claim Rejections 35 U.S.C. 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

2. Claims 23-41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kaddurah-Daouk (US 5,998,457) in view of Meisner (US 4,772,591), Grant et al. (US 5,888,553), Beale (US 5,756,469) and Beale (US 5,716,926).

3. Kaddurah-Daouk teaches a method of treating osteoporosis or osteoarthritis comprising administering therapeutical effective amount of creatine compound, or a pharmaceutical acceptable salt, to patient. See, particularly, the abstract, table 1-2, and claims 1-12. As to the amount of creatine administered, Kaddurah-Daouk states: "the actual amount of drug needed will be depend on factors such as the size, age, and severity of disease in afflicted individual. ... for this invention the creatine compound will be administered at dosage and period of time effective to reduce, ameliorate or eliminate the symptoms of the disease." Col. 11, lines 24-44.

4. Kaddurah-Daouk does not teach expressly the employment of creatine pyruvate for the treatment, or the particular amount administered, or the method may be employed for promoting growth and mineralization of bone; improving acceptance and osseous integration of bone; or accelerating healing as claimed herein, or the purity as herein required.

5. However, Grant et al. teaches that the excess of cortisol is known to be a cause of osteoporosis, tissue degeneration, and an anabolic composition with anticortisol effect are used to balance effect of cortisol. The anabolic composition comprising creatine or its salts, wherein the amount of creatine or its salts is in the range of 1-10,000 mg. See, column 1, line 52 bridging column 2, line 59, column 5, lines 56-65, column 13, lines 8-9, and claim 8. Meisner teaches a method for accelerated wound healing or treating degenerative disorders including periodontal disease, osteoarthritis, comprising administering a composition comprising creatine to an animal or human. See, particularly, column 1, line 28 bridging column 2, line 45, column 5, lines 3 bridging column 7, line 10. Beale ('469) teaches creatine pyruvate (pyruvyl-creatine) is particularly useful as cortisol antagonist or cortisol blocker for prevent the catabolic activity of cortisol. See column 1, lines 7-18, 54-60; column 3, lines 46-63, and column 5, lines 54-60. Beale ('926) further teaches that pyruvate is known to be useful for treating osteoporosis. See, claim 24.

Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed the invention was made, to employ creatine pyruvate composition, for improving bone conditions, or for accelerating healing of pathogenic bone conditions, including bone implantation and defect bone caused by trauma or otherwise. Note claims 23 and 24 read

on the composition comprising creatine pyruvate, since creatine pyruvate is both a creatine salt, and a pyruvate.

A person of ordinary skill in the art would have been motivated to employ creatine pyruvate composition, for improving bone conditions, or for accelerating healing of pathogenic bone conditions, including bone implantation and defect bone caused by trauma or otherwise. because creatine and pyruvate, either alone, or in combinations are known to be useful for improving bone conditions. Further, it is prima facie obvious to combine two compounds each of which is taught in the prior art to be useful for same purpose in order to form third composition that is to be used for very the same purpose; idea of combining them flows logically from their having been individually taught in prior art; thus, the claimed invention which employ a combination (salt) of two compounds known to be useful for treating osteoporosis sets forth prima facie obvious subject matter. See In re Kerkhoven, 205 USPQ 1069. Note treating osteoporosis is to promoting minerization of bone. Further, creatine pyruvate is particularly known to be useful for treating disease associated with cortisol activity and connective tissue degenerative disorders is known to be closely related to cortisol activity. Finally, creatine is known to be useful for promoting tissue repair process, and treating osteoarthritis and osteoporosis would also considered as a process of promoting tissue (cartilage) repairing since one of the major symptoms of osteoarthritis and osteoporosis is tissue degeneration. Finally, The optimization of a result effective parameter, e.g., the effective amount of creatine, particularly within the range of the prior art, is considered within the skill of the artisan, absent evidence to the contrary. See, In re Boesch and Slaney (CCPA) 204 USPQ 215. Furthermore, the instant claims are essentially directed to a particular salt of creatine for treating disorders known to be

treated by creatine, or its derivatives, or its salts. Absent evidence to the contrary, the employment of pyruvate creatine is seen to be a selection from amongst equally suitable material and as such obvious. Ex parte Winters 11 USPQ 2nd 1387 (at 1388). It is well settled that in the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed.Cir. 1990).

Response to the Arguments

Applicants' amendments and remarks submitted April 17, 2007 have been fully considered, but are not persuasive.

Applicants assert that since the cited references do not teach expressly the particular patient population herein required, i.e., patients with bone implant, or with bone defect caused by trauma or surgery, the claimed inventions are not obvious over the cited references. The examiner respectfully disagrees. Note the cited references as a whole teaches that creatine are useful for improving bone conditions, as evidenced by treatment of o osteoporosis, osteoarthritis or periodontitis, or for accelerating wound healing, promoting growth of connective tissue (cartilage). Therefore, one of ordinary skill in the art would have been motivated to use creatine, or its salts for treatment of bone conditions that requires improving bone conditions. Note, question under 35 U.S.C. 103 is not merely what reference expressly teach, but what they would have suggested to one of ordinary skill in the art at the time the invention was made; all disclosures of prior art, including unpreferred embodiments, must considered. In re Lamberti and Konort (CCPA), 192 USPQ 278.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang whose telephone number is (571) 272-0632. The examiner can normally be reached on Monday to Friday from 7:00 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SHENGJUN WANG
PRIMARY EXAMINER

Shengjun Wang
Primary Examiner
Art Unit 1617